Radiofrequency Ablation in Primary Aldosteronism

 

 Permissions and Reprints

Abstract

The radiofrequency ablation (RFA) technique has been extensively used in the treatment of primary malignancies and metastases and has been recently deployed for the treatment of unilateral primary aldosteronism (PA) as an alternative to whole unilateral adrenalectomy.

Current evidence comparing RFA with unilateral adrenalectomy in the treatment of PA so far has been variable, with studies being retrospective and small-scale, but it remains a very attractive option as a potentially less invasive treatment option compared to adrenalectomy.

This review article describes the procedure, and provides evidence and the possible future direction of RFA in the treatment of unilateral PA.

Publication History

Received: 24 April 2023
Received: 22 June 2023

Accepted: 05 July 2023

Accepted Manuscript online:
13 July 2023

Article published online:
11 August 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Donlon P, Dennedy MC. Thermal ablation in adrenal disorders: A discussion of the technology, the clinical evidence and the future. Curr Opin Endocrinol Diabetes Obes 2021; 28: 291-302 DOI: 10.1097/MED.0000000000000627.
  CrossrefPubMedGoogle Scholar
• 2 Zhang H, Li Q, Liu X. et al. Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: An efficacy and safety, proof-of-principle trial. J Clin Hypertens (Greenwich) 2020; 22: 1618-1626 DOI: 10.1111/jch.13960.
  CrossrefPubMedGoogle Scholar
• 3 Zhao Z, Liu X, Zhang H. et al. Catheter-based adrenal ablation remits primary aldosteronism: A randomized medication-controlled trial. Circulation 2021; 144: 580-582 DOI: 10.1161/CIRCULATIONAHA.121.054318.
  CrossrefPubMedGoogle Scholar
• 4 Wu X, Senanayake R, Goodchild E. et al. [(11)C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: A prospective, within-patient trial. Nat Med 2023; DOI: 10.1038/s41591-022-02114-5.
  CrossrefPubMedGoogle Scholar
• 5 Costa N, Mounie M, Gombault-Datzenko E. et al. Cost analysis of radiofrequency ablation for adrenal adenoma in patients with primary aldosteronism and hypertension: Results from the ADERADHTA pilot study and comparison with surgical adrenalectomy. Cardiovasc Intervent Radiol 2022; DOI: 10.1007/s00270-022-03295-9.
  CrossrefPubMedGoogle Scholar
• 6 Rossi GP, Bernini G, Caliumi C. et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300 DOI: 10.1016/j.jacc.2006.07.059.
  CrossrefPubMedGoogle Scholar
• 7 Brown JM, Siddiqui M, Calhoun DA. et al. The unrecognized prevalence of primary aldosteronism: A cross-sectional study. Ann Intern Med 2020; 173: 10-20 DOI: 10.7326/M20-0065.
  CrossrefPubMedGoogle Scholar
• 8 Bouhanick B, Delchier MC, Lagarde S. et al. Radiofrequency ablation for adenoma in patients with primary aldosteronism and hypertension: ADERADHTA, a pilot study. J Hypertens 2021; 39: 759-765 DOI: 10.1097/HJH.0000000000002708.
  CrossrefPubMedGoogle Scholar
• 9 Williams TA, Lenders JWM, Mulatero P. et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 2017; 5: 689-699 DOI: 10.1016/S2213-8587(17)30135-3.
  CrossrefPubMedGoogle Scholar
• 10 Chini EN, Brown MJ, Farrell MA. et al. Hypertensive crisis in a patient undergoing percutaneous radiofrequency ablation of an adrenal mass under general anesthesia. Anesth Analg 2004; 99: 1867-1869 DOI: 10.1213/01.ANE.0000136803.54212.E1.
  CrossrefPubMedGoogle Scholar
• 11 Dhaliwal A, Kolli S, Dhindsa BS. et al. Efficacy of EUS-RFA in pancreatic tumors: Is it ready for prime time? A systematic review and meta-analysis. Endosc Int Open 2020; 8: E1243-E1251 DOI: 10.1055/a-1221-5012.
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Sarwar A, Brook OR, Vaidya A. et al. Clinical outcomes following percutaneous radiofrequency ablation of unilateral aldosterone-producing adenoma: Comparison with adrenalectomy. J Vasc Interv Radiol 2016; 27: 961-967 DOI: 10.1016/j.jvir.2016.03.042.
  CrossrefPubMedGoogle Scholar
• 13 Yang MH, Tyan YS, Huang YH. et al. Comparison of radiofrequency ablation versus laparoscopic adrenalectomy for benign aldosterone-producing adenoma. Radiol Med 2016; 121: 811-819 DOI: 10.1007/s11547-016-0662-1.
  CrossrefPubMedGoogle Scholar
• 14 Abbas A, Idriz S, Railton NJ. et al. Image-guided ablation of Conn’s adenomas in the management of primary hyperaldosteronism. Clin Radiol 2013; 68: 279-283 DOI: 10.1016/j.crad.2012.06.137.
  CrossrefPubMedGoogle Scholar
• 15 Liu SY, Chu CM, Kong AP. et al. Radiofrequency ablation compared with laparoscopic adrenalectomy for aldosterone-producing adenoma. Br J Surg 2016; 103: 1476-1486 DOI: 10.1002/bjs.10219.
  CrossrefPubMedGoogle Scholar
• 16 Beland MD, Mayo-Smith WW. Ablation of adrenal neoplasms. Abdom Imaging 2009; 34: 588-592 DOI: 10.1007/s00261-008-9462-y.
  CrossrefPubMedGoogle Scholar
• 17 Williams TA, Gomez-Sanchez CE, Rainey WE. et al. International histopathology consensus for unilateral primary aldosteronism. J Clin Endocrinol Metab 2021; 106: 42-54 DOI: 10.1210/clinem/dgaa484.
  CrossrefPubMedGoogle Scholar
• 18 Cano-Valderrama O, Gonzalez-Nieto J, Abad-Cardiel M. et al. Laparoscopic adrenalectomy vs. radiofrequency ablation for the treatment of primary aldosteronism. A single center retrospective cohort analysis adjusted with propensity score. Surg Endosc 2022; 36: 1970-1978 DOI: 10.1007/s00464-021-08481-3.
  CrossrefPubMedGoogle Scholar
• 19 Szejnfeld D, Nunes TF, Giordano EE. et al. Radiofrequency ablation of functioning adrenal adenomas: Preliminary clinical and laboratory findings. J Vasc Interv Radiol 2015; 26: 1459-1464 DOI: 10.1016/j.jvir.2015.06.019.
  CrossrefPubMedGoogle Scholar
• 20 Argentesi G, Wu X, Goodchild E. et al. Preliminary data from FABULAS: A feasibility study of RadioFrequency endoscopic ABlation, with ULtrasound guidance, as a non-surgical, Adrenal Sparing treatment for aldosterone producing adenomas. Endocrine Abstracts 2022; 153 DOI: 10.1530/endoabs.86.P153.
  CrossrefPubMedGoogle Scholar